Future international management of African horse sickness vaccines

  • J. A. House
Conference paper

Summary

Three types of African horse sickness (AHS) vaccine, namely adult mouse brain, modified live vaccine and inactivated viral vaccine (IVV) are reviewed. The results of efficacy trials carried out with each vaccine type highlight the advantages of the IVV. Vaccination with African horse sickness virus serotype 4 IVV, given as 2 separate doses, provided full protection against subsequent, homologous challenge. The absence of any detectable viraemia after challenge would also prevent infection of insect vectors. The advantages of establishing international vaccine banks for AHS are discussed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander RA, Du Toit PJ (1934) The immunization of horses and mules against horsesickness by means of the neurotropic virus of mice and guinea pigs. Onderstepoort J Vet Sei 2: 375–391Google Scholar
  2. 2.
    Anderson J, Mertens PPC, Herniman KAJ (1993) A competitive ELISA for the detection of anti-tubule antibodies using monoclonal antibody against bluetongue virus nonstructural protein NS 1. J Virol Methods 43: 167–176PubMedCrossRefGoogle Scholar
  3. 3.
    Anonymous (1992) African horse sickness. In: Manual of standards for diagnostic tests and vaccines. Office International Des Epizooties, Paris pp 91–100Google Scholar
  4. 4.
    Burroughs JN, O’Hara R, Smale CJ, Hamblin C, Walton A, Armstrong R, Mertens PPC (1994) Purification and properties of virus particles, infectious sub-viral particles, cores and VP7 crystals of African horse sickness virus serotype 9. J Gen Virol 75: 1849–1857PubMedCrossRefGoogle Scholar
  5. 5.
    Coetzer JAW, Erasmus BJ (1994) African horsesickness. In: Coetzer JAW, Thomson GR, Tustin RC (eds) Infectious diseases of livestock, vol 1. Oxford University Press, Oxford, pp 460–475Google Scholar
  6. 6.
    Cowley JA, Gorman BM (1989) Cross-neutralisation of genetic reassortants of blue-tongue virus serotypes 20 and 21. Vet Microbiol 19: 37–51PubMedCrossRefGoogle Scholar
  7. 7.
    Dubourget P, Preaud JM, Detraz N, Lacoste F, Fabry AC, Erasmus B, Lombard M (1992) Development, production and quality control of an industrial inactivated vaccine against AHS type IV. In: Walton TE, Osburn BI (eds) Bluetongue, Africa horse sickness and related orbiviruses. Proc 2nd Int Symp. CRC Press, Boca Raton, pp 874–886Google Scholar
  8. 8.
    Erasmus BJ (1965) The attenuation of viscerotropic horsesickness virus in tissue culture. Bull Off Int Epiz 64: 697–702Google Scholar
  9. 9.
    Erasmus BJ (1966) The attenuation of African horsesickness virus: problems associated with the use of different host systems. In: Proc 1st Int Conf Equine Inf Dis, Stresa 1966, pp 208–213Google Scholar
  10. 10.
    Erasmus BJ (1972) The pathogenesis of African horse sickness. In: Proc 3rd Int Conf Equine Inf Dis, Paris, pp 1–11Google Scholar
  11. 11.
    Erasmus BJ (1976) A new approach to polyvalent immunization against African horse-sickness. In: Bryans JT, Gerber H (eds) Equine infectious diseases. Veterinary Publications, Princeton, pp 401–403Google Scholar
  12. 12.
    Hamblin C, Mellor PS, Graham SD, Hooghuis H, Montejano RC, Cubillo MA, Boned J (1991) Antibodies in horses, mules and donkeys following monovalent vaccination against African horse sickness. Epidemiol Infect 106: 365–371PubMedCrossRefGoogle Scholar
  13. 13.
    House JA, House C (1989) Immunization studies on African horse sickness. Proc 93rd Ann Mtg US Animal Health Assoc, pp 357–365Google Scholar
  14. 14.
    House JA, House C, Mebus CA (1992) A review of African horse sickness with emphasis on selected vaccines. Ann NY Acad Sci 653: 228–232PubMedCrossRefGoogle Scholar
  15. 15.
    House JA, Lombard M, House C, Dubourget P, Mebus CA (1992) Efficacy of an inactivated vaccine for African horse sickness virus serotype 4. In: Walton TE, Osburn BI (eds) Proc 2nd Int Symp bluetongue, African horse sickness and related orbiviruses. CRC Press, Boca Raton, pp 891–895Google Scholar
  16. 16.
    House JA, Lombard M, Dubourget P, House C, Mebus CA (1994) Further studies on the efficacy of an inactivated African horse sickness serotype vaccine. Vaccine 12: 142–144PubMedCrossRefGoogle Scholar
  17. 17.
    Howell PG (1963) Observations on the occurrence of African horsesickness amongst immunised horses. Onderstepoort J Vet Res 30: 3–10Google Scholar
  18. 18.
    Laviada MD, Roy P, Vizcaino-Sanchez JM, Casal JI (1995) The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Vir Res 38: 205–218CrossRefGoogle Scholar
  19. 19.
    O’Hara RS, Meyer AJ, Pullen L, Martin LA, Mertens PPC (1998) Development of a mouse model system and identification of the individual genome segments of African horse sickness virus serotypes 3 and 8 involved in determination of virulence. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York, pp 259–279 (Arch Virol [Suppl] 14 )Google Scholar
  20. 20.
    Martin LA, Meyer AJ, O’Hara RS, Fu H, Knowles NJ, Mertens PPC (1998) Phylogenetic analysis of African horse sickness virus genome segment 10: Does sequence variation influence virulence characteristics? In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York, pp 281–293 (Arch Virol [Suppl] 14 )Google Scholar
  21. 21.
    Mellor PS (1990) The replication of bluetongue virus in Culicoides vectors. Curr Top Microbiol Immunol 162: 143–161PubMedGoogle Scholar
  22. 22.
    Mertens PPC, Pedley S, Cowley J, Burroughs JN, Corteyn AH, Jeggo MH, Jennings DM, Gorman BM (1989) Analysis of the roles of bluetongue outer capsid proteins, VP2 and VP5, in determination of virus serotype. Virology 170: 561–565PubMedCrossRefGoogle Scholar
  23. 23.
    Moss SR, Ayres CM, Nuttall PA (1987) Assignment of the genome segment coding for the neutralising epitope(s) of Orbiviruses in the Great Island serogroup ( Kemerovo serogroup ). Virology 157: 137–144PubMedCrossRefGoogle Scholar
  24. 24.
    Nuttall PA, Moss SR, Jones LD, Carey D (1989) Identification of the major genetic determinant for neurovirulence of tick-borne orbiviruses. Virology 172: 428–434PubMedCrossRefGoogle Scholar
  25. 25.
    Nuttall PA, Moss SR, Carey D, Jones LD, Jacobs SC (1990) Genetic determinants modulating the pathogenic phenotype of tick-borne orbiviruses. Virology 174: 430–435PubMedCrossRefGoogle Scholar
  26. 26.
    Nuttall PA, Jacobs SC, Jones LD, Carey D, Moss SR (1992) Enhanced neurovirulence of tick-borne orbiviruses resulting from genetic modulation. Virology 187: 407–412PubMedCrossRefGoogle Scholar
  27. 27.
    Nobel TA, Neumann F (1961) Vaccination against African horse sickness and postvaccination reactions in Israel. OAH Vaccine Readings, pp 168–173Google Scholar
  28. 28.
    Ozawa Y, Bahrami S (1966) African horse-sickness killed-virus tissue culture vaccine. Can J Comp Med Vet Sci 30: 311–314PubMedGoogle Scholar
  29. 29.
    Pavri KM, Anderson CR (1963) Isolation of a vaccine strain of African horse-sickness virus from brains of two horses given polyvalent vaccine. Ind J Vet Sci 33: 215–219Google Scholar
  30. 30.
    Roy P (1998) New generation of African horse sickness vaccines based on structural and molecular studies of the virus particles. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York, pp 177–202 (Arch Virol [Suppl] 14 )Google Scholar
  31. 31.
    Shah KV, Chinoy DN, Gokhale TB (1963) Investigations of African horse-sickness in India. II. Reactions in non-immune horses after vaccination with the polyvalent African horse-sickness vaccine. Ind J Vet Sci 34: 2: 75–83Google Scholar
  32. 32.
    Swanepoel R, Erasmus BJ, Williams R, Taylor MB (1991) Encephalitis and chorioretinitis associated with neurotropic African horsesickness virus infection in laboratory workers. III. Virological and serological investigations. S Afr Med J 81: 458–461Google Scholar
  33. 33.
    Wade-Evans AM, Pullen L, Hamblin C, O’Hara RS, Burroughs JN, Mertens PPC (1998) VP7, from African horse sickness virus serotype 9, protects mice against a lethal heterologous serotype challenge. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York, pp 211–219 (Arch Virol [Suppl] 14 )Google Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • J. A. House
    • 1
  1. 1.United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary ServicesNational Veterinary Services Laboratory, Foreign Animal Diseases Diagnostic LaboratoryGreenport, Plum IslandUSA

Personalised recommendations